Home | Contact | Employees | Incident Reporting | Sitemap | Santen Worldwide
Text Size
  • A
  • A
  • A
  • Menu
  • About Us
  • .
  • About Santen
  • .
  • Social Responsibility
  • .
  • Products/R&D
  • .
  • Careers
  • .
  • Customer Information

Home ›

Santen and IAPB Partner to Advocate for Better Eye Health

Posted Feb 5, 2021

Notice of Commencement of Preparation for Transition to a Holding Company Structure through Sole-Share Transfer and Change in Fiscal Year

Posted Feb 4, 2021

Santen Reports the 3rd Quarter Fiscal 2020 Consolidated Performance

Posted Feb 4, 2021

(Timely Disclosure) Notice of Commencement of Preparation for Transition to a Holding Company and Change in Fiscal Year

Posted Feb 4, 2021

Santen and Ube Announces U.S. FDA Acceptance of New Drug Application for STN10117 (DE-117) (JAN: Omidenepag Isopropyl) as a Treatment for Patients with Glaucoma and Ocular Hypertension

Posted Feb 2, 2021

Santen and Ube Announces Launch of Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in South Korea

Posted Feb 1, 2021

Corporate Social Responsibility (CSR) page on our website has been updated

Posted Jan 8, 2021

Santen Joins the Valuable 500 International Initiative Promoting the Active Participation of People with Disabilities

Posted Jan 7, 2021

Contact

Advanced Vision Science welcomes your inquiries and opinions. Contact
  • Privacy Policy
  • I
  • Terms of Use
  • I
  • Accessibility Statement
© 2021 Advanced Vision Science. All Rights Reserved.
Created by NDIC